SEC Form 4 · accession 0001019056-18-001110
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marvin L White
Officer — President and CEO · Director
Period of report
Dec 4, 2018
Accepted (ET)
Dec 6, 2018 · 10:23 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 4, 2018 | P | 10,000 | $2.38 | A | 203,603 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchase price of $2.38 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $2.38 to $2.39. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.